MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saxena, N. C.
Right arrow Articles by Macdonald, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saxena, N. C.
Right arrow Articles by Macdonald, R. L.

0026-895X/97/020328-08$3.00/0
Copyright © by The American Society for Pharmacology and Experimental Therapeutics
All rights of reproduction in any form reserved.
MOLECULAR PHARMACOLOGY 51:328-335 (1997).

Contrasting Actions of Lanthanum on Different Recombinant gamma -Aminobutyric Acid Receptor Isoforms Expressed in L929 Fibroblasts

Nina C. Saxena,1 Torben R. Neelands, and Robert L. Macdonald

Departments of Neurology (N.C.S., T.R.N.) and Physiology (R.L.M.), University of Michigan Medical School, Ann Arbor, Michigan 48104-1687

    Summary
Summary
Introduction
Materials & Methods
Results
Discussion
References

Functional studies have indicated that, unlike most divalent cations, lanthanum increases both native and recombinant gamma -aminobutyric acid (GABA) receptor (GABAR) currents. In the present study, we have examined whether lanthanum shows subunit-dependent selectivity for modification of currents from different GABAR isoforms. The effects of lanthanum on three different GABAR isoforms, alpha 1beta 3gamma 2L, alpha 6beta 3gamma 2L, and alpha 6beta 3delta , were determined by transient expression of combinations of alpha 1, alpha 6, beta 3, gamma 2L, and delta  subunit cDNAs in L929 fibroblasts. Whole-cell recording was used to determine the concentration-response curves for lanthanum for the three different isoforms at submaximal concentrations of GABA. Lanthanum displayed strong potentiation of alpha 1beta 3gamma 2L GABAR currents consistent with earlier reports of potentiation of GABAR currents by lanthanum in neurons and recombinant GABAR isoforms. However, in contrast to the potentiation of alpha 1beta 3gamma 2L GABAR currents by lanthanum, alpha 6beta 3delta GABAR currents were strongly inhibited and alpha 6beta 3gamma 2L GABAR currents were weakly inhibited by lanthanum. Interaction of lanthanum with GABAR isoforms was competitive, with lanthanum decreasing the EC50 value for GABA of alpha 1beta 3gamma 2L GABARs without changing the maximum current and increasing the EC50 value for GABA of alpha 6beta 3delta and alpha 6beta 3gamma 2L GABAR currents (greater shift in EC50 value in the alpha 6beta 3delta compared with the alpha 6beta 3gamma 2L GABARs) without changing the maximum GABAR current. Neither potentiation nor inhibition of GABAR currents by lanthanum showed any voltage dependence. These results suggest that 1) changing the alpha -subunit subtype from alpha 1 to alpha 6 altered the effect of lanthanum from potentiation to inhibition, 2) changing the gamma 2L subunit to the delta -subunit changed the level of maximal inhibition of alpha 6 subtype-containing GABAR currents by lanthanum, and 3) the site for interaction with lanthanum probably was on the extracellular surface of GABARs.

    Introduction
Summary
Introduction
Materials & Methods
Results
Discussion
References

Lanthanum is a trivalent cation and is the most electropositive element of the rare earth group. Its mechanisms of action at the cellular and molecular level have not been studied extensively until recently. Functional studies have indicated that lanthanum, unlike most divalent cations, increases GABA-activated currents in both native and recombinant GABARs (1-4). Based on earlier studies suggesting that changes in subunit composition produced recombinant receptors with differential selectivity toward benzodiazepines and the divalent cation zinc, we formulated this study to determine whether lanthanum displays similar subunit-dependent selectivity toward different GABAR isoforms. There is considerable interest in the effects of lanthanum and its compounds on cellular systems from a neurotoxicological point of view due to its increasing use in industry and therapeutics (5). There is evidence in cell culture and animal systems to suggest that micromolar concentrations of lanthanum can exert cytotoxic effects (6). Study of the cytotoxicity of lanthanum chloride in a pulmonary macrophage primary culture system indicated an half-maximum lethal concentration of 52 µM (7). Traces of lanthanum (0.5 µg/g) were detected in the bones of man and animals after exposure (8). More recent studies of autopsy specimens from deceased smelter factory workers exposed to lanthanum have indicated a 2- to 16-fold increase in lanthanum levels, compared with nonexposed controls; lanthanum levels were highest in those who died of lung cancer (5).

A number of different approaches have been taken to understand the mechanism of action of lanthanum and other heavy metals. Behavioral, anatomical, and biochemical approaches have been useful in identifying the overall toxic effects, structural changes in various regions of the nervous system and biochemical modifications caused by toxicants. However, functional studies using electrophysiological techniques could provide information about the cellular and molecular mechanisms of action of heavy metals and suggest how they alter the excitability of the nervous system and lead to behavioral changes (4). In the present study, we have compared and contrasted the effects of lanthanum on the electrophysiological properties of three different putative cerebellar GABAR isoforms transiently expressed in L929 fibroblasts using the whole-cell recording configuration. Specifically, we have examined the effects of changes in subunit subtype composition (among the three GABAR isoforms) on the nature and extent of modulation of GABAR currents by lanthanum. Our results demonstrate GABAR subunit-dependent actions of lanthanum.

    Materials and Methods
Summary
Introduction
Materials & Methods
Results
Discussion
References

Plasmid construction. Full-length cDNAs encoding the rat alpha 1, beta 3, and delta  GABAR subunits were kindly provided by Dr. A. J. Tobin (alpha 1; University of California, Los Angeles), Dr. D. B. Pritchett (beta 3; University of Pennsylvania, Philadelphia, PA) and Dr. K. Angelides (delta ; Baylor College of Medicine, Houston, TX) in the bluescript vector. The rat gamma 2L and alpha 6 subunits were cloned in our laboratory by Fang Tan (University of Michigan, Ann Arbor, MI). The rat cDNAs have been described previously (see Ref. 9 for review). The plasmids were cut with appropriate restriction enzymes to release the complete open reading frames and 10-100 bp of the 5' and 3' untranslated regions, including the Kozak sequences (10, 11). These plasmids were subcloned individually into the BglII site of the mammalian expression vector pCMVNeo (12) to form the plasmids pCMVralpha 1, pCMVralpha 6, pCMVrbeta 3, pCMVrgamma 2L, and pCMVrdelta . A 3000 bp BglII fragment of pSV2beta gal [obtained from Dr. Audrey Seasholtz (University of Michigan, Ann Arbor, MI) (13)] was subcloned into pCMVNeo to create the vector pCMVbeta gal.

Preparation of gridded dishes. Individual 35-mm tissue culture dishes (Corning Glassworks, Corning, NY) were imprinted with a 26 × 26 grid (300 µm per grid edge) on the bottom with a Mecanex BB form 2 device (Medical Systems, Greenvale, NY) according to the manufacturer's instructions. After plating at low density, cells could be accurately located relative to a particular grid, identified by a corresponding two-letter alphabetic code, while switching between the fluorescent and the electrophysiology microscopes. The process of imprinting the grid removed some of the negative charges required for cell adherence, necessitating a coating of one or two drops of collagen (0.5 mg/ml) in PBS for optimal adherence of L929 cells. The gridded region of the dish was coated with collagen and UV-sterilized overnight before cells were plated on it.

Cell culture and DNA transfection. L929 cells were grown in Dulbecco's modified Eagle's medium with 10% horse serum along with 100 IU/ml of penicillin and 100 µg/ml of streptomycin at 37° in 5% CO2/95% air. Cells were passaged the night before they were to be transfected with trypsin/EDTA solution (0.5% and 0.2%, respectively) and plated at 70% confluency (500,000 cells per 60-mm dish) in a 60-mm dish. The next day, cells were transfected with various combinations of CsCl-banded pCMVralpha 1, pCMVralpha 6, pCMVrbeta 3, pCMVrgamma 2L, pCMVrdelta , and pCMVrbeta gal plasmids, using a modified calcium phosphate precipitation method (14). Plasmids were mixed in a 1:1:1 (alpha :beta :beta gal) or 1:1:1:1 (alpha :beta :gamma :beta gal or alpha :beta :delta :beta gal) ratio while maintaining the total amount of DNA added per dish at 16-20 µg in 500 µl of transfection buffer. Cells were shocked with a 15% glycerol/1 × PBS solution for 30 sec, 4 or 5 hr after the addition of precipitate. Cells were passaged as above 24 hr after addition of precipitate and placed in 15-ml conical tubes and treated with 375 µg/ml tissue culture grade DNase I for 5 min (twice, for a total time of treatment with DNase I of 10 min) at 37°. Cells were pelleted at 400 × g and plated onto either standard 35-mm plates or mecanex-gridded plates. Electrophysiological analysis was performed 24 hr later.

Galactosidase staining protocols. Two different beta -galactosidase staining protocols were used to identify cells transfected with pCMVbeta gal. To determine the transfection efficiency, 5-bromo-4-chloro-3-indoyl beta -D-galactosidase staining of cells was performed as described previously (15). FDG staining was performed as originally described by Nolan et al. (16), with some modifications for use with adherent cells, to identify positively transfected cells for electrophysiological recordings. Cells were washed twice with PBS to remove the medium and incubated for 5 min at 37° with 1 ml of PBS to re-equilibrate the cells to this temperature. While the cells were incubating, 20 mM FDG solution prepared by the manufacturer (Molecular Probes, Eugene, OR) was diluted 1:20 by adding 25 µl of the 20 mM FDG solution into 500 µl of 0.5 × PBS in a 1.5-ml microcentrifuge tube and placed in a 37° water bath. After 5 min of incubation, PBS was aspirated from the cells, and the warmed 1-mM FDG solution (final concentration) was added to the cells. The plate with the cell and FDG solution was warmed in the 37° water bath for 1 min, placed on ice, and then 2.5 ml of ice-cold 1 × PBS was added. After 5 min on ice, the cells were viewed with a fluorescence microscope fitted with fluorescein filters.

Recording solutions and electrodes. Before recording, the PBS/FDG solution on the plate of cells was exchanged with five 2-ml washings of external recording medium containing the following: 142 mM NaCl, 8.1 mM KCl, 6 mM MgCl2, 1 mM CaCl2, 10 mM glucose, 10 mM HEPES, pH ~7.4. The internal (intrapipette) solution contained 153 mM KCl, 1 mM MgCl2, 5 mM EGTA, 10 mM HEPES, pH ~7.3. This combination of external and intrapipette solutions produced a chloride equilibrium potential of -1.4 mV and a potassium equilibrium potential of -75 mV across the patch membrane. GABA was diluted with external recording solution from a stock solution (100 mM or 10 mM in distilled water) to the indicated final concentration on the day of the experiment. A multipuffer application system (50-90 µm tip diameter) was used to apply a range of different concentrations of drugs for experiments.

Micropipettes and recording electrodes were fabricated on a Flaming Brown micropipette puller (Model P-87; Sutter Instruments). Microhematocrit capillary tubes made of sodalime glass (i.d., 1.1-1.2 mm; absorbance, 1.3-1.4 mm; Fisher Scientific, Pittsburgh, PA) were used to fabricate the recording electrodes; a type of borosilicate glass with filament (absorbance, 1.2 mm; World Precision Instruments, New Haven, CT) and a pyrex, nonfilament custom glass tubing (i.d., 0.6 mm; absorbance, 1.2 mm; Drummond Scientific Co., Broomall, PA) were used for the pressure ejection micropipettes and a multipuffer application system, respectively. Recording electrodes were coated with Q-Dope before use and had resistances ranging from 5 to 10 MOmega when filled with the internal solution and immersed in a dish containing the external solution.

Multipuffer system to apply a range of different concentrations of drugs. To enable fast application of a number of different concentrations and types of drug, a multipuffer application system was designed in the laboratory (17). Briefly, it consisted of a T-tube device with inlet and outlet ports feeding into a common application port at one end and individually connected to polyethylene tubing leading to either a reservoir of different solutions to be tested (inlet tubing) or the waste flask (outlet tubing) at the other end. Puffer tips between 50 and 90 µm in diameter made of nonfilament glass were inserted into the application port. A suction pump (aquarium air pump; Supra, Oakland, NJ) was connected to the outlet tubing of the U-tube device via a three-way miniature solenoid valve (General Valve, Fairfield, NJ) operated by a valve driver (Valve driver II; General Valve). To apply a drug, the valve was turned off (regulated by timer), stopping the suction of solution through the U-tube device and pushing the resultant column of accumulated solution in the application port out through the puffer tip. Reactivation of the valve resumed flow of solution through the U tube and suction of the applied drug/solution from the bath, thus affecting a washout of the drug from the area around the puffer tip and cell. The multipuffer application system was tested for a satisfactory rate of application and removal of drug from the bath before every experiment using the dye, fast green (Sigma Chemical, St. Louis, MO) in a petri dish filled with distilled water. The rate of application and removal of the solutions depended on the size of the tip and its position relative to the cell [tau between 30 and 70 msec, measuring tip potential between potassium-free (0 mM KCl) and potassium-containing (120 mM KCl) solutions].

Whole-cell recordings and analyses. Whole-cell recording was performed with methods described previously for mouse spinal cord neuron recordings (18, 19) using a List L/M EPC-7 amplifier (List Electronics, Darmstadt, Germany). All recordings were made at room temperature (22-24°). Currents were recorded simultaneously on a video cassette recorder (Sony SL-HF360; Sony, Tokyo, Japan) via a digital audio processor (Sony PCM-501 ES, 14-bit, 44 kHz), on Axotape (Version 2; Axon Instruments, Burlingame, CA; using an Axon TL-1-40 16-channel, 40-kHz, 12-bit interface) on a IBM-compatible 80286 personal computer and a chart recorder (Gould, Cleveland, OH) for later computer analysis. Whole-cell recordings were low-pass filtered (3 db at 1 kHz, 8-pole Bessel filter; Frequency Devices, Haverhill, MA) before the chart recorder. The peak whole-cell current amplitudes were measured either using Axotape or directly from the chart output and reported as mean ± standard error. Statistical tests of significance were performed using paired Student's t test for all drug treatments and the p values were reported. Concentration response curves were fitted to a four-parameter logistic function R = Rmin + (Rmax - Rmin)/(1 + 10)Log EC50 -X)n), where X is logarithm of drug concentration, R is the response to drug, Rmax is the maximum drug response, Rmin is the minimum drug response, Log EC50 = X value when the response is halfway between maximum and minimum, and n is the Hill slope, a unitless variable that controls the slope of the curve (Prism; GraphPAD Software, San Diego, CA).

    Results
Summary
Introduction
Materials & Methods
Results
Discussion
References

GABA responsiveness of transfected L929 cells. Previous work from our laboratory has shown that six putative cerebellar GABAR isoforms, alpha 1beta 3gamma 2L, alpha 1beta 2gamma 2L, alpha 6beta 3gamma 2L, alpha 6beta 2gamma 2L, alpha 6beta 3delta , and alpha 1beta 2gamma L GABARs, show high levels of functional expression after transient transfection in mouse fibroblast L929 cells (20). Concentration response curves for GABA corresponding to alpha 1beta 3gamma 2L, alpha 6beta 3gamma 2L, and alpha 6beta 3delta GABAR isoforms showed typical sigmoidal shapes with different EC50 values for GABA and maximal GABA-evoked current amplitudes. The alpha 6beta 3delta GABARs displayed an EC50 value of 0.3 µM and a maximum current amplitude of 371 ± 116 pA (eight experiments), the alpha 6beta 3gamma 2L GABARs showed an EC50 value of 2 µM and a maximum current amplitude of 730 ± 305 pA (nine experiments), and the alpha 1beta 3gamma 2L GABARs exhibited an EC50 value of 14 µM and a maximum current amplitude of 803 ± 141 pA (nine experiments) (20).

Modulation of GABAR currents by the polyvalent cation lanthanum. To determine the effect of lanthanum on the three putative cerebellar GABAR isoforms, we examined the effect of 300 µM lanthanum on GABA-evoked alpha 6beta 3delta , alpha 6beta 3gamma 2L, and alpha 1beta 3gamma 2L whole-cell currents at submaximal concentrations of GABA (close to the respective EC50 values for GABA). The concentrations used were 0.3, 3, and 10 µM GABA for the alpha 6beta 3delta , alpha 6beta 3gamma 2L, and alpha 1beta 3gamma 2L GABAR isoforms, respectively (Fig. 1). 300 µM lanthanum enhanced 10 µM GABA-evoked alpha 1beta 3gamma 2L currents to 145 ± 12% (mean ± standard error, n = 8) of the control current evoked by GABA alone. In contrast, it did not potentiate alpha 6beta 3gamma 2L and alpha 6beta 3delta GABAR currents, blocking alpha 6beta 3gamma 2L currents by 30 ± 10% (mean ± standard error, n = 8) and alpha 6beta 3delta currents by 81 ± 5% (mean ± standard error, n = 8) (Fig. 2).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of 300 µM lanthanum on GABA-evoked whole-cell currents recorded from L929 cells transfected with alpha 1beta 3gamma 2L, alpha 6beta 3gamma 2L, and alpha 6beta 3delta GABAR subtypes. Cells were voltage-clamped at -75 mV, and 5-sec pulses of submaximal concentrations of GABA with and without 300 µM lanthanum were applied via pressure-ejection micropipette placed close to the cells. Downward deflections, inward currents (efflux of negatively charged chloride ions) at -75 mV (ECl = 0 mV). Horizontal bars above the current traces, the duration of application of GABA. The recovery of current amplitudes after washout of lanthanum to pretreatment values indicates reversibility of the effect of lanthanum.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 2.   Normalized concentration-response curves for lanthanum corresponding to cells transfected with alpha 1beta 3gamma 2L (A), alpha 6beta 3gamma 2L (B), and alpha 6beta 3delta (C) GABAR subtypes. Symbols, mean values of current amplitudes as a percent of maximum current induced by 10, 3, and 0.3 µM GABA for the alpha 1beta 3gamma 2L (n = 4), alpha 6beta 3gamma 2L (n = 8), and alpha 6beta 3delta (n = 8) GABAR isoforms, respectively, in the absence of lanthanum. Vertical bars, mean ± standard error.

To further characterize the differential modulation by lanthanum of alpha 1beta 3gamma 2L, alpha 6beta 3gamma 2L, and alpha 6beta 3delta GABAR currents, concentration response curves for lanthanum were obtained at submaximal concentrations of GABA. The current amplitudes were expressed as percentages of the current evoked by GABA in the absence of lanthanum. The concentration response curves for lanthanum were fitted using a four-parameter logistic equation (Prism, GraphPAD Software; see eq. 1). Normalized current amplitudes were plotted as a function of increasing concentrations of lanthanum (Fig. 2). Lanthanum (1 mM) potentiated alpha 1beta 3gamma 2L GABAR currents to a maximum of 164 ± 11% (n = 8, p < 0.001) of control current in the absence of lanthanum with an EC50 value of 210 ± 61 µM and Hill slope of 1.5. In contrast to the potentiation of alpha 1beta 3gamma 2L GABAR currents by lanthanum, the alpha 6beta 3delta GABAR currents were strongly inhibited and alpha 6beta 3gamma 2L GABAR currents were weakly inhibited by lanthanum. The alpha 6beta 3gamma 2L GABAR currents displayed maximal inhibition of 32 ± 9% (n = 7, p < 0.003) at 3 mM lanthanum with an IC50 value of 117 ± 32 µM and Hill slope of -1.1, and the alpha 6beta 3delta GABAR currents showed maximal inhibition of 83 ± 4% (n = 7; p < 0.000007) at 600 µM lanthanum with and IC50 value of 29 ± 6 µM and Hill slope of -1.3 (Fig. 2, B and C).

The potentiation of alpha 1beta 3gamma 2L GABA currents was, however, lower at 3 mM lanthanum compared with that at 1 mM lanthanum [141 ± 9% (n = 8, p < 0.003) and 164 ± 11% of control current, respectively]. At higher concentrations of lanthanum, there was no significant potentiation or inhibition of the current in the presence of lanthanum as compared with the control current in the absence of lanthanum. The average currents in the presence of 6 and 10 mM lanthanum were 97 ± 11% (n = 3, p = 0.8) and 87 ± 16% (n = 3, p = 0.5) of the control current, respectively. This suggested that alpha 1beta 3gamma 2L GABA currents were potentiated only at concentrations of lanthanum below 1 mM. At concentrations higher than 1 mM, the potentiating effect of lanthanum decreased, and at 10 mM lanthanum, the alpha 1beta 3gamma 2L GABA current approached the control current in the absence of lanthanum. The decrease in potentiation of alpha 1beta 3gamma 2L GABAR currents occurred at concentrations of lanthanum higher than 1 mM with an IC50 value (for the decrease in potentiation) of 4.3 ± 0.6 mM and a Hill slope of -3.8.

Competitive interaction between lanthanum ions and GABAR isoforms. To elucidate the mechanism of potentiation and inhibition of different GABAR isoforms by lanthanum, GABA concentration response curves were compared in the absence and presence of the corresponding EC50 and IC50 values of lanthanum for each of the three GABAR isoforms. The current amplitudes in the absence and presence of lanthanum were normalized to the maximum current evoked by GABA in the absence of lanthanum. The data were fitted by the logistic equation described in Materials and Methods. In the presence of 300 µM lanthanum, the concentration response curve for alpha 1beta 3gamma 2L GABARs was shifted to lower concentrations of GABA with no increase in the maximum current evoked by GABA (Fig. 3A). The EC50 value for GABA in the absence of lanthanum was 13 ± 3.3 µM and the Hill slope was 1.5 ± 0.1 (n = 4). In the presence of 300 µM lanthanum, the EC50 value for GABA was decreased to 6.4 ± 3 µM and the Hill slope was not significantly changed at 2.0 ± 0.2 (n = 4). The decrease in EC50 value for GABA was statistically significant (p = 0.01) using paired Student's t test, and the Hill slope was not changed significantly (p = 0.18). Therefore, lanthanum decreased the GABA EC50 value for alpha 1beta 3gamma 2L GABARs without changing the maximum current, suggesting that lanthanum increased the affinity of GABA for the alpha 1beta 3gamma 2L GABARs without changing the number of functional receptors. Unlike the alpha 1beta 3gamma 2L GABAR isoform, concentration response curves for the alpha 6beta 3gamma 2L and alpha 6beta 3delta GABAR isoforms were shifted to higher concentrations of GABA in the presence of lanthanum with no decrease in the maximum GABA-evoked current. The increases in EC50 value for GABA were statistically significant (p < 0.05). The EC50 value for GABA was increased from 2.5 ± 0.2 µM to 4.4 ± 0.1 µM GABA in the presence of 100 µM lanthanum (p = 0.004, n = 4) for the alpha 6beta 3gamma 2L GABAR isoform (Fig. 3B), and the EC50 value for alpha 6beta 3delta GABAR isoform was increased from 0.38 ± 0.05 µM to 1.06 ± 0.23 µM GABA in the presence of 30 µM lanthanum (p = 0.04, n = 5) (Fig. 3C). The Hill slope for alpha 6beta 3gamma 2L GABAR currents was decreased from 1.48 ± 0.09 to 1.22 ± 0.09 (p = 0.003, n = 4), and that for alpha 6beta 3delta GABAR currents was altered from 1.22 ± 0.15 to 1.15 ± 0.17 (p = 0.8, n = 5). Therefore, lanthanum decreased the GABA affinity for the alpha 6beta 3gamma 2L and alpha 6beta 3delta GABAR isoforms without altering the number of active receptors.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 3.   Competition curves for GABA and lanthanum for alpha 1beta 3gamma 2L, alpha 6beta 3gamma 2L, and alpha 6beta 3delta GABAR isoforms. Concentration response curves for GABA were obtained in the absence and presence of 300 µM lanthanum (alpha 1beta 3gamma 2L; A), 100 µM lanthanum (alpha 6beta 3gamma 2L; B), and 30 µM lanthanum (alpha 6beta 3delta ; C). Symbols, mean values (n = 3) of currents normalized to the maximum current evoked in the absence of lanthanum from three cells each for each of the three different isoforms. Vertical bars, mean ± standard error.

Voltage independence of the effect of lanthanum on different GABAR isoforms. To gain some insight regarding the location of the site of interaction between lanthanum and GABAR chloride channel, the voltage dependence of GABAR currents was examined in the presence and absence of lanthanum (Fig. 4). The current-voltage relationship in the presence of GABA alone was largely linear for the alpha 1beta 3gamma 2L and alpha 6beta 3gamma 2L isoforms (Fig. 4, A and B) with reversal potentials of 0 and -6 mV, respectively, and it showed some departure from linearity for the alpha 6beta 3delta isoform with a reversal potential of +5 mV (Fig. 4C). The average values of the reversal potentials for the three isoforms in the absence and presence of lanthanum were 4.3 ± 2.4 and 4.9 ± 1.4 mV (alpha 1beta 3gamma 2L, n = 6, p = 0.7), -2.0 ± 2.4 and -2.5 ± 2.0 mV (alpha 6beta 3gamma 2L, n = 6, p = 0.8) and 3.8 ± 0.3 and 5.7 ± 2.5 mV (alpha 6beta 3delta , n = 5, p = 0.5), respectively. There was no change in the current-voltage relationship in the presence of lanthanum for any of the three GABAR isoforms studied, consistent with voltage-independent potentiation and inhibition by lanthanum.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Current-voltage relationships for alpha 1beta 3gamma 2L, alpha 6beta 3gamma 2L, and alpha 6beta 3delta GABAR isoforms in the absence and presence of lanthanum. Representative current-voltage curves for GABA currents evoked in the absence and presence of lanthanum are shown for alpha 1beta 3gamma 2L (10 µM GABA+300 µM lanthanum; A), alpha 6beta 3gamma 2L (3 µM GABA+100 µM lanthanum; B), and alpha 6beta 3delta (0.3 µM GABA+30 µM lanthanum; C) GABAR isoforms. Step changes in holding voltage were applied for voltages ranging from -75 mV to +60 mV.

    Discussion
Summary
Introduction
Materials & Methods
Results
Discussion
References

Subunit-dependent inhibition and potentiation of different GABAR isoforms by lanthanum. In contrast to the mainly inhibitory effects of divalent cations, the trivalent cation lanthanum has been shown to enhance GABAR currents in rat DRG neurons (2) and in recombinant alpha 1beta 2 and alpha 1beta 2gamma 2 GABARs expressed in human embryonic kidney (A293) cells (3). Reichling and MacDermott (1) reported a biphasic effect of lanthanum on rat dorsal horn neurons: at concentrations between 1 and 100 µM, lanthanum-enhanced GABAR currents to a maximum of 130% of control, whereas at higher concentrations, lanthanum markedly reduced GABAR currents (1).

The present study further clarifies the interactions between lanthanum and GABARs by demonstrating contrasting actions, inhibition and potentiation, of lanthanum on different recombinant GABARs and by adding a structural basis to the distinctive actions of lanthanum on GABARs, which suggest that changing the alpha -subunit subtype from alpha 1 to alpha 6 alters the effect of lanthanum on GABARs from potentiation to inhibition at comparable (micromolar) concentrations of lanthanum. It further suggests that the level of maximal inhibition of GABAR currents by lanthanum in alpha 6-containing GABAR isoforms is greater in the presence of the delta  subunit (83%) than in the presence of a gamma  subunit (32%), probably due to a greater shift in the EC50 value for GABA in delta -containing receptors (3-fold; 0.38 to 1.2 µM) compared with gamma -containing receptors (2-fold; 2.5 to 4.4 µM). Comparison of the modulatory effects of 100 µM lanthanum on the three different GABAR isoforms demonstrated its contrasting actions, showing distinct potentiation of alpha 1beta 3gamma 2L GABAR currents (20 ± 7%, n = 8, p = 0.026), marked inhibition of alpha 6beta 3delta GABAR currents (71 ± 4%, n = 8, p < 0.0003), and weak inhibition of alpha 6beta 3gamma 2L GABAR currents (19 ± 8%, n = 8, p < 0.0002). Therefore, the structural change associated with the presence of the alpha 1 subtype instead of the alpha 6 subunit resulted in a functional change from inhibition to potentiation by lanthanum, whereas the change associated with the presence of the delta  instead of the gamma subunit resulted in increased maximal inhibition by lanthanum. This could explain, at least in part, reports of biphasic effects of lanthanum on GABAR currents (1) and the lack thereof (2) because the manifestation of the biphasic effects of lanthanum would depend on the differences in composition of functional GABAR isoforms present in the different regions studied (dorsal horn versus dorsal root ganglion neurons), their relative abundance, and the concentration of GABA (100 µM versus 10 µM) studied. The loss of potentiation of alpha 1beta 3gamma 2L GABAR currents by lanthanum at concentrations above 1 mM also could underlie the manifestation of biphasic effects of lanthanum on GABAR currents in dorsal horn neurons (1). In the presence of both alpha 1beta 3gamma 2L and alpha 6beta 3delta -like GABAR isoforms, it is conceivable that, at lower concentrations of lanthanum (0.1 to 100 µM), the enhancing effect of lanthanum could dominate, whereas at higher concentrations of lanthanum (300 µM to 3 mM), loss of potentiation of the alpha 1beta 3gamma 2L-like isoform by lanthanum could result in unmasking of the inhibitory effect of lanthanum on the alpha 6beta 3delta -like isoform. This corresponds well with the maximum potentiation (35%) and inhibition (80%) of GABA-evoked currents and the corresponding concentrations of lanthanum (30 µM and 3 mM, respectively) at which the effects occurred, in the biphasic response seen in dorsal horn neurons by Reichling and MacDermott (1). Region-specific distribution of different GABAR subunit mRNAs has been demonstrated in the rat brain (21, 22), whereas immunoprecipitation studies have revealed the presence of specific GABAR isoforms in the rat cerebellum and cerebral cortex (23-25). Recent immunohistochemical analysis of GABAR heterogeneity in rat spinal cord also showed colocalization of different subunit subtypes in distinct laminar compartments (26). Although alpha 6 and delta  subunits could not be detected in the spinal cord, alpha 1, alpha 2, and alpha 5 subunit subtypes showed restricted, lamina-specific distribution whereas the alpha 3 subtype showed widespread expression. Therefore, region-specific expression of different GABAR isoforms composed of different alpha  subunit subtypes in the presence or absence of gamma  or delta  subunits in the dorsal horn versus dorsal root ganglion neurons could underlie the differences in the observed effects of lanthanum between the two studies.

This study also indicates that the presence of the delta  subunit increases the efficacy of inhibition of GABAR currents by lanthanum, implying a correlation between the structural change represented by delta  subunit instead of gamma  subunit and the functional change in inhibition of GABAR currents from 83% in delta -containing GABAR isoforms to 32% in gamma -containing GABAR isoforms. Although not identical, this is consistent with our report of no significant potentiation of alpha 1beta 1delta isoform by lanthanum (300 µM lanthanum) and distinct potentiation by lanthanum of the alpha 1beta 1 isoform (27). The structural determinant of lanthanum potentiation contributed by the alpha 1 subunit in the alpha 1beta 1 GABARs could be countered by a reverse contribution from the delta  subunit in the alpha 1beta 1delta isoform, giving rise to the lack of effect of lanthanum seen in the alpha 1beta 1delta isoform. However, this result must be interpreted with caution because the effect of lanthanum on GABAR currents was studied at single, specific concentrations of lanthanum (300 µM) and GABA (10 µM). Moreover, due to the low efficiency of expression of alpha 6beta 3 GABARs in our expression system (20), we could not compare the action of lanthanum on alpha 6beta 3 GABARs with those on alpha 6beta 3delta and alpha 6beta 3gamma 2L GABARs to provide further evidence for this hypothesis. The presence of different subtypes of the beta  subunit (beta 1 versus beta 3) also could potentially play a role in determining the effect of lanthanum on different GABAR isoforms. Knowledge of subunit selectivity of lanthanum could be instrumental in characterizing the molecular properties of GABARs and in understanding the regional and developmental diversity of neuronal GABARs.

Extracellular location of site for lanthanum interaction. Results from the present study suggest that the site of interaction with lanthanum lies on the extracellular surface of GABARs. First, the quick onset and removal of the effect of lanthanum during acute application (5-sec pulses) of lanthanum in the whole-cell recording configuration suggests that the action is mediated by an extracellular event. Second, the competitive nature of potentiation and inhibition by lanthanum with respect to GABA also suggests that the site of interaction between GABARs and lanthanum is likely to be extracellular. Third, the lack of a clear voltage dependence in the current-voltage relationship in the presence of lanthanum as compared with that in its absence also suggests that the site for lanthanum interaction sensed little or none of the transmembrane electrical gradient and, therefore, was likely to be extracellular. Earlier work by Ma and Narahashi (2) also suggested that the potentiation by lanthanum was nearly voltage independent, whereas that of Im et al. (3) suggested weak voltage dependence. Based on our results, the extracellular lanthanum interaction site on GABAR is subject to characteristic functional modulation by the alpha -subunit subtype (potentiation versus inhibition) and the gamma /delta subunits (extent of inhibition) and, therefore, might be composed mainly of contributions from the extracellular regions of at least the alpha  and gamma /delta subunits.

Physiological implications of enhancement and inhibition of distinct GABAR isoforms by lanthanum. Potentiation of the alpha 1-containing and inhibition of the alpha 6-containing (putative) cerebellar GABAR isoforms by lanthanum might increase the plasticity of the cerebellum from a therapeutic or functional perspective. GABAergic neurotransmission has been proposed to play an important role in the perception of pain. Selective depression of noxiously evoked activity from rat and feline spinal cord neurons by intravenous injection of midazolam and clinical control of pain by subarachnoid infusion of midazolam have been reported (28-30). It has been postulated that pain perception is modulated in the substantia gelatinosa (lamina II), which controls impulse transmission from the primary afferents to projecting neurons (31, 32). By demonstrating a striking segregation of distinct GABAR subunits in functionally different neuron populations in the substantia gelatinosa (alpha 2, alpha 3) and in projecting neurons (alpha 1), Bohlhalter et al. (26) have suggested differential modulation of GABAergic neurotransmission by specific pharmacological agents and pharmacological control of nociception and treatment of neurogenic pain based on GABAA receptor heterogeneity in the future. Lanthanum administered into the lumbar subarachnoid space of rat has been shown to have antinociceptive effects (33). Based on the subunit-specific modulation of GABAR currents by lanthanum described in the present study, lanthanum could be an important resource in the functional characterization of GABAR isoforms in the substantia gelatinosa and projecting neurons ultimately providing insights into the role of receptor heterogeneity in signal processing and mechanisms of pain.

Based on the increasingly diverse applications of lanthanum-containing compounds in industry and therapeutics (5), the distinct actions of lanthanum on different GABAR isoforms offer potential tools to understand the structural and functional diversity of GABARs in nature and to envision more receptor-specific targeting of drugs in pathophysiological situations.

    Footnotes

Received August 1, 1996; Accepted October 31, 1996

1   Current affiliation: Department of Physiology, Emory University, Atlanta, GA 30322.

   This work was supported by a Grant NS33300 from the National Institute for Neurological Disorders and Stroke (R.L.M.).

Send reprint requests to: Dr. Robert L. Macdonald, Neuroscience Laboratory Building, 1103 East Huron Street, Ann Arbor, MI 48104-1687.

    Abbreviations

GABA, gamma -aminobutyric acid; GABAR, GABAA receptor; PBS, phosphate-buffered saline; FDG, fluorescein di-beta -galactopyranoside; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; EGTA, ethylene glycol bis(beta -aminoethyl ether)-N,N,N',N'-tetraacetic acid.

    References
Summary
Introduction
Materials & Methods
Results
Discussion
References

1. Reichling, D. B. and A. MacDermott. Lanthanum actions on excitatory amino acid-gated currents and voltage-activated Ca2+ currents in rat dorsal horn neurons. J. Physiol.  441:199-218 (1991). [Abstract/Free Full Text]
2. Ma, J. Y. and T. Narahashi. Differential modulation of GABAA receptor-channel complex by polyvalent cations in rat dorsal root ganglion neurons. Brain Res.  607:222-232 (1993)[Medline].
3. Im, M. S., B. J. Hamilton, D. B. Carter, and W. B. Im. Selective potentiation of GABA-mediated Cl- current by lanthanum ion in subtypes of cloned GABAA receptors. Neurosci. Lett.  144:165-168 (1992)[Medline].
4. Narahashi, T., J. Y. Ma, O Arakawa, E. Reuveny, and M. Nakahiro. GABA receptor-channel complex as a target site of mercury, copper, zinc and lanthanides. Cell. Mol. Neurobiol.  14:599-621 (1994)[Medline].
5. Das, T., A. Sharma, and G. Talukder. Effects of lanthanum in cellular systems. A review. Biol. Trace Elem. Res.  18:201-228 (1988)[Medline].
6. Haley, T. J. Pharmacology, and toxicology of the rare earth elements. J. Pharm. Sci.  54:663-670 (1965)[Medline].
7. Palmer, R. J., J. L. Butenhoff, and J. B. Stevens. Cytotoxicity of the rare earth metals cerium, lanthanum, and neodymium in vitro: comparisons with cadmium in a pulmonary macrophage primary culture system. Environ. Res.  43:142-156 (1987)[Medline].
8. Venogopal, B. and T. D. Luckey. Metal Toxicity in Mammals. Vol. 2. Plenum Press, New York, 135 (1980).
9. Macdonald, R. L. and R. W. Olsen. GABAA receptor channels. Annu. Rev. Neurosci.  17:569-602 (1994)[Medline].
10. Kozak, M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res.  9:5233-5262 (1981)[Abstract/Free Full Text].
11. Kozak, M. Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res.  12:857-872 (1984)[Abstract/Free Full Text].
12. Hugenvik, J. I., M. W. Collard, R. E. Stofko, A. F. Seasholtz, and M. D. Uhler. Regulation of the human enkephalin promoter by the two isoforms of the catalytic subunit of cyclic adenosine 3',5'-monophosphate-dependent protein kinase. Mol. Endocrinol.  5:921-930 (1991)[Abstract/Free Full Text].
13. Hall, C. V., P. E. Jacob, G. M. Ringold, and F. Lee. Expression and regulation of Escherichia coli lac Z gene fusions in mammalian cells. J. Mol. Appl. Genet.  2:101-109 (1983)[Medline].
14. Chen, C. and H. Okayama. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol.  7:2745-2752 (1987)[Abstract/Free Full Text].
15. Sanes, J. R., J. L. R. Rubenstein, and J. F. Nicolas. Use of a recombinant retrovirus to study post-implantation cell lineage in mouse embryos. EMBO J.  5:3133-3142 (1986)[Medline].
16. Nolan, G. P., S. Fiering, J. F. Nicolas, and L. A. Herzenberg. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on beta -D-galactosidase activity after transduction of Escherichia coli lacZ. Proc. Natl. Acad. Sci. USA  85:2603-2607 (1988)[Abstract/Free Full Text].
17. Greenfield, L. J. and R. L. Macdonald. Whole-cell and single-channel alpha 1beta 1gamma 2S GABAA receptor currents elicited by a "multi-puffer" drug application device. Pfluegers Arch. Eur. J. Physiol.  432:1080-1090 (1996). [Medline]
18. Macdonald, R. L., C. J. Rogers, and R. E. Twyman. Kinetic properties of GABAA receptor main conductance state of mouse spinal cord neurones in culture. J. Physiol. (Lond.)  410:479-499 (1989)[Abstract/Free Full Text].
19. Porter, N. M., R. E. Twyman, M. D. Uhler, and R. L. Macdonald. Cyclic AMP-dependent protein kinase decreases GABAA receptor current in mouse spinal cord neurons. Neuron  5:789-796 (1990)[Medline].
20. Saxena, N. C. and R. L. Macdonald. Properties of putative cerebellar gamma -aminobutyric acidA receptor isoforms. Mol. Pharmacol.  49:567-579 (1996)[Abstract].
21. Laurie, D. J., P. H. Seeburg, and W. Wisden. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J. Neurosci.  12:1063-1076 (1992)[Abstract].
22. Wisden, W., D. J. Laurie, H. Monyer, and P. H. Seeburg. The distribution of 13 GABAA receptor subunit messenger RNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J. Neurosci.  12:1040-1062 (1992)[Abstract].
23. Quirk, K., N. P. Gillard, C. I. Ragan, P. J. Whiting, and R. M. McKernan. Model of subunit composition of gamma -aminobutyric acid-A receptor subtypes expressed in rat cerebellum with respect to their alpha  and delta  subunits. J. Biol. Chem.  269:16020-16028 (1994)[Abstract/Free Full Text].
24. Khan, Z. U., A. Gutierrez, and A. L. De Blas. The subunit composition of a GABAA/benzodiazepine receptor from rat cerebellum. J. Neurochem.  63:371-374 (1994)[Medline].
25. Pollard, S., M. J. Duggan, and F. A. Stephenson. Further evidence for the existence of alpha  subunit heterogeneity within discrete gamma -aminobutyric acidA receptor subpopulations. J. Biol. Chem.  268:3753-3757 (1993)[Abstract/Free Full Text].
26. Bohlhalter, S., O. Weinmann, H. Mohler, and J.-M. Fritschy. Laminar compartmentalization of GABAA-receptor subtypes in the spinal cord: an immunohistochemical study. J. Neurosci.  16:283-297 (1996)[Abstract/Free Full Text].
27. Saxena, N. C. and R. L. Macdonald. Assembly of GABAA receptor subunits: role of the delta  subunit. J. Neurosci.  14:7077-7086 (1994)[Abstract].
28. Clavier, N., M. Lombard, and J. Besson. Benzodiazepines and pain: effects of midazolam on the activities of nociceptive non-specific dorsal horn neurons in the rat spinal cord. Pain  48:61-71 (1992)[Medline].
29. Sumida, T., M. Tagami, Y. Ide, M. Nagase, H. Sekiyama, and K. Hanaoka. Intravenous midazolam suppresses noxiously evoked activity of spinal wide dynamic range neurons in cats. Anesth. Analg.  80:58-63 (1995)[Abstract].
30. Schoeffler, P., P. Auroy, J. E. Bazin, J. Taxi, and A. Woda. Subarachnoid midazolam: histologic study in rats and report of its effect on chronic pain in humans. Reg. Anesth.  16:329-332 (1991)[Medline].
31. Melzack, R. and P. D. Wall. Pain mechanism: a new theory. Science (Washington D. C.)  150:971-979 (1965)[Free Full Text].
32. Wall, P. D. The substantia gelatinosa. A gate control mechanism set across sensory pathway. Trends Neurosci.  3:221-224 (1990).
33. Reddy, S. V. R. and T. L. Yaksh. Antinociceptive effects of lanthanum neodymium and europium following intrathecal administration. Neuropharmacology  19:181-185 (1980)[Medline].


Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
C. J. Herden, N. E. Pardo, R. K. Hajela, Y. Yuan, and W. D. Atchison
Differential Effects of Methylmercury on {gamma}-Aminobutyric Acid Type A Receptor Currents in Rat Cerebellar Granule and Cerebral Cortical Neurons in Culture
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 517 - 528.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. Mizokami, T. Kanematsu, H. Ishibashi, T. Yamaguchi, I. Tanida, K. Takenaka, K. I. Nakayama, K. Fukami, T. Takenawa, E. Kominami, et al.
Phosholipase C-Related Inactive Protein Is Involved in Trafficking of {gamma}2 Subunit-Containing GABAA Receptors to the Cell Surface
J. Neurosci., February 14, 2007; 27(7): 1692 - 1701.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
J. Glykys and I. Mody
Hippocampal Network Hyperactivity After Selective Reduction of Tonic Inhibition in GABAA Receptor {alpha}5 Subunit-Deficient Mice
J Neurophysiol, May 1, 2006; 95(5): 2796 - 2807.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. C. Drafts and J. L. Fisher
Structural Determinants of the Pharmacological Properties of the GABAA Receptor {alpha}6 Subunit
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1108 - 1115.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. L. Fisher
Amiloride Inhibition of gamma -Aminobutyric AcidA Receptors Depends upon the alpha Subunit Subtype
Mol. Pharmacol., June 1, 2002; 61(6): 1322 - 1328.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. R. Neelands and R. L. Macdonald
Incorporation of the pi Subunit into Functional gamma -Aminobutyric AcidA Receptors
Mol. Pharmacol., September 1, 1999; 56(3): 598 - 610.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
T. R. Neelands, J. Zhang, and R. L. Macdonald
GABAA Receptors Expressed in Undifferentiated Human Teratocarcinoma NT2 Cells Differ from Those Expressed by Differentiated NT2-N Cells
J. Neurosci., August 15, 1999; 19(16): 7057 - 7065.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. R. Neelands, J. L. Fisher, M. Bianchi, and R. L. Macdonald
Spontaneous and gamma -Aminobutyric Acid (GABA)-Activated GABAA Receptor Channels Formed by epsilon  Subunit-Containing Isoforms
Mol. Pharmacol., January 1, 1999; 55(1): 168 - 178.
[Abstract] [Full Text]


Home page
J. Physiol.Home page
W. J. Zhu, J. F. Wang, L. Corsi, and S. Vicini
Lanthanum-mediated modification of GABAA receptor deactivation, desensitization and inhibitory synaptic currents in rat cerebellar neurons
J. Physiol., September 15, 1998; 511(3): 647 - 661.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
T. R. Neelands, L. J. Greenfield Jr, J. Zhang, R. S. Turner, and R. L. Macdonald
GABAA Receptor Pharmacology and Subtype mRNA Expression in Human Neuronal NT2-N Cells
J. Neurosci., July 1, 1998; 18(13): 4993 - 5007.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. Horenstein and M. H. Akabas
Location of a High Affinity Zn2+ Binding Site in the Channel of alpha 1beta 1 gamma -Aminobutyric AcidA Receptors
Mol. Pharmacol., May 1, 1998; 53(5): 870 - 877.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
J. L. Fisher, J. Zhang, and R. L. Macdonald
The Role of alpha 1 and alpha 6 Subtype Amino-Terminal Domains in Allosteric Regulation of gamma -Aminobutyric Acida Receptors
Mol. Pharmacol., October 1, 1997; 52(4): 714 - 724.
[Abstract] [Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saxena, N. C.
Right arrow Articles by Macdonald, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saxena, N. C.
Right arrow Articles by Macdonald, R. L.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1997 by the American Society for Pharmacology and Experimental Therapeutics